Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety-related claims are consistent with the provided label excerpts (especially hypocalcemia risk in advanced CKD). However, the evaluation is limited because the provided label text only contains specific sections on hypocalcemia/mineral metabolism and does not substantiate many other claims (e.g., indications, mechanism details, specific adverse reactions).
Category Scores
Accurate Statements
In patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m2), including dialysis-dependent patients, Prolia is associated with a greater risk of severe hypocalcemia, which can include hospitalization, life-threatening events, and fatal cases.
Supported by Warnings & Precautions (5.1 Patients with Advanced Chronic Kidney Disease), Use in Specific Populations (8.6 Renal Impairment), Adverse Reactions postmarketing (6.2), and Patient Counseling (17).
Unsupported Statements
Prolia contains the active ingredient denosumab.
Not supported by the provided label excerpts.
Prolia is a prescription medication used to treat osteoporosis in postmenopausal women at high risk for fracture.
Indication claims are not supported by the provided label excerpts.
Prolia is used to treat men at high risk for fracture.
Indication claims are not supported by the provided label excerpts.
Prolia is used to treat adults with bone loss due to certain cancer treatments.
Indication claims are not supported by the provided label excerpts.
Prolia is used to treat giant cell tumor of bone that is unresectable.
Indication claims are not supported by the provided label excerpts.
Prolia is used to treat giant cell tumor of bone when surgical resection is likely to result in severe morbidity.
Indication claims are not supported by the provided label excerpts.
Prolia works by inhibiting osteoclast activity, which reduces bone breakdown.
Mechanism description is not supported by the provided label excerpts.
There are no approved generic versions of Prolia available in the United States.
Not supported by the provided label excerpts.
Prolia is manufactured by Amgen.
Not supported by the provided label excerpts.
Prolia is a human monoclonal antibody.
Not supported by the provided label excerpts.
Prolia targets RANK ligand (RANKL).
Mechanism/target claims are not supported by the provided label excerpts.
RANKL plays a critical role in the formation, function, and survival of osteoclasts.
Mechanism biology statements are not supported by the provided label excerpts.
Osteoclasts are responsible for bone resorption (breakdown).
Mechanism biology statements are not supported by the provided label excerpts.
Denosumab binds to RANKL and prevents it from interacting with its receptor RANK on the surface of osteoclast precursors and mature osteoclasts.
Mechanism binding interaction details are not supported by the provided label excerpts.
By inhibiting osteoclast activity and bone resorption, Prolia increases bone mineral density.
Clinical pharmacology/efficacy claim is not supported by the provided label excerpts.
By reducing osteoclast activity and bone resorption, Prolia reduces the risk of fractures.
Clinical pharmacology/efficacy claim is not supported by the provided label excerpts.
Common side effects of Prolia include pain in the extremities.
No 'common side effects' list for this specific symptom is provided in the label excerpts.
Common side effects of Prolia include muscle spasms.
No 'common side effects' list for this specific symptom is provided in the label excerpts.
Common side effects of Prolia include urinary tract infections.
No 'common side effects' list for this specific symptom is provided in the label excerpts.
Prolia can cause hypocalcemia (low calcium levels).
Hypocalcemia risk is supported in provided sections, but this statement is overly general and does not specify 'severe' hypocalcemia; still, it is partially supported. If strictly judged to the excerpts only, severe hypocalcemia is explicitly supported, not generic 'hypocalcemia' phrasing as 'can cause' without severity context.
Prolia can cause severe allergic reactions.
Not supported by the provided label excerpts.
Prolia can cause osteonecrosis of the jaw.
Not supported by the provided label excerpts.
Prolia can cause atypical femur fractures.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Any administration/dosing instructions and lab monitoring details required for safe use (e.g., calcium/vitamin D supplementation requirements; timing of serum calcium and mineral checks) for the broader set of claims beyond advanced CKD.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Only one evaluated claim (advanced CKD hypocalcemia risk including hospitalization/life-threatening/fatal cases) is directly supported by the provided label excerpts. Many other claims (indications, mechanism, and multiple adverse reactions) are not supported by the supplied label text, creating a risk of misinformation if relied upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Most claims are not supported by the provided label excerpts; only the advanced CKD hypocalcemia warning is substantiated.
Suggested Improvement
Restrict the response to label-supported information from the provided excerpts (primarily severe hypocalcemia risk in advanced CKD, supplementation, and recommended monitoring), or provide the relevant label sections for indications, mechanism, and specific adverse reactions.